Drug developed by Ohio State Consortium shows promise in treating COVID-19 patients at high-risk for ARDS in Phase 3 study
The drug was partially developed by James Dalton during his time at Ohio State and the intellectual property exclusively licensed on a global basis by Veru is owned jointly by Ohio State, the University of Tennessee and Oncternal Therapeutics, Inc.
The drug was partially developed by James Dalton during his time at Ohio State and the intellectual property exclusively licensed on a global basis by Veru is owned jointly by Ohio State, the University of Tennessee and Oncternal Therapeutics, Inc.